肺癌筛查中的人工智能身体成分分析:超越肺癌检出的附加价值
本研究对NLST中20768名参与者的基线低剂量胸部CT进行AI自动身体成分测量,评估其在肺癌发生、肺癌死亡、心血管病死亡和全因死亡风险预测中的附加价值。
要点
- AI自动身体成分测量可改善肺癌死亡、心血管病死亡和全因死亡的预测。
- AI身体成分测量未改善肺癌发生的风险预测。
- 身体成分指标来自基线低剂量胸部CT,无需额外扫描。
核心结论
- 自动从基线低剂量CT导出的身体成分测量对肺癌死亡、心血管病死亡和全因死亡有附加预测价值,但对肺癌发生无附加预测价值。
研究设计与样本
- NLST二次分析,纳入20768名参与者,中位年龄61岁(IQR 57-65),男性12317名,使用先前开发的AI算法从基线低剂量胸部CT导出身体成分测量。
诊断标准与关键数值
- 身体成分测量包括骨骼肌和皮下脂肪组织的面积与衰减属性,由AI算法自动导出。
- 使用性别和死因特异性Cox比例风险模型评估附加价值,模型调整年龄、体质指数、定量肺气肿、冠状动脉钙化、糖尿病/心脏病/高血压/卒中病史及其他PLCOM2012肺癌风险因素。
- 拟合优度改善用似然比检验评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background An artificial intelligence (AI) algorithm has been developed for fully automated body composition assessment of lung cancer screening noncontrast low-dose CT of the chest (LDCT) scans, but the utility of these measurements in disease risk prediction models has not been assessed. Purpose To evaluate the added value of CT-based AI-derived body composition measurements in risk prediction of lung cancer incidence, lung cancer death, cardiovascular disease (CVD) death, and all-cause mortality in the National Lung Screening Trial (NLST). Materials and Methods In this secondary analysis of the NLST, body composition measurements, including area and attenuation attributes of skeletal muscle and subcutaneous adipose tissue, were derived from baseline LDCT examinations by using a previously developed AI algorithm. The added value of these measurements was assessed with sex- and cause-specific Cox proportional hazards models with and without the AI-derived body composition measurements for predicting lung cancer incidence, lung cancer death, CVD death, and all-cause mortality. Models were adjusted for confounding variables including age; body mass index; quantitative emphysema; coronary artery calcification; history of diabetes, heart disease, hypertension, and stroke; and other PLCOM2012 lung cancer risk factors. Goodness-of-fit improvements were assessed with the likelihood ratio test. Results Among 20 768 included participants (median age, 61 years [IQR, 57-65 years]; 12 317 men), 865 were diagnosed with lung cancer and 4180 died during follow-up. Including the AI-derived body composition measurements improved risk prediction for lung cancer death (male participants: χ2 = 23.09, P < .001; female participants: χ2 = 15.04, P = .002), CVD death (males: χ2 = 69.94, P < .001; females: χ2 = 16.60, P < .001), and all-cause mortality (males: χ2 = 248.13, P < .001; females: χ2 = 94.54, P < .001), but not for lung cancer incidence (male participants: χ2 = 2.53, P = .11; female participants: χ2 = 1.73, P = .19). Conclusion The body composition measurements automatically derived from baseline low-dose CT examinations added predictive value for lung cancer death, CVD death, and all-cause death, but not for lung cancer incidence in the NLST. Clinical trial registration no. NCT00047385 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Fintelmann in this issue.
引用
- Xu K, Khan MS, Li TZ, et al. AI Body Composition in Lung Cancer Screening: Added Value Beyond Lung Cancer Detection. Radiology. 2023. PMID: 37489991. doi:10.1148/radiol.222937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。